利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.011 秒)

    PATTERN RECOGNITION OF SERUM PROTEINS FOR THE DIAGNOSIS OR TREATMENT OF PHYSIOLOGIC CONDITIONS
    1.
    发明公开
    PATTERN RECOGNITION OF SERUM PROTEINS FOR THE DIAGNOSIS OR TREATMENT OF PHYSIOLOGIC CONDITIONS 审中-公开
    血清蛋白诊断和治疗生理学莱顿模式识别

    公开(公告)号：EP1711811A1

    公开(公告)日：2006-10-18

    申请号：EP04703675.1

    申请日：2004-01-20

    申请人： Cedars-Sinai Medical Center

    发明人： AGUS, David, B. ,  KVAMME, Mark, D.

    IPC分类号： G01N33/48 ,  G06F17/11 ,  G06F17/15

    CPC分类号： G06F19/24 ,  G06F19/28

    摘要： Systems and methods of diagnosing and/or treating physiologic conditions based upon pattern recognition of serum protein profiles are provided. Mass spectrometry or other conventional techniques for creating a profile of serum proteins is employed, and a patient's profile is thereafter digitized for computational analysis. A pattern recognition algorithm is implemented to determine a degree of similarity between the patient's profile and other profiles stored in a database along with information describing the pathologic state of the individuals from whom such data was obtained. The degree of similarity may provide an indication of, for example, the way in which the patient may react to a particular clinical treatment or their predisposition to a particular disease condition. The methods and system of the present invention may be used to monitor the dynamic progression of disease pathology in a patient, and may be implemented via a computer network.

    USE OF BENZOTHIOPENES TO TREAT AND PREVENT PROSTATE CANCER
    2.
    发明公开
    USE OF BENZOTHIOPENES TO TREAT AND PREVENT PROSTATE CANCER 审中-公开
    BENZOTHIOPENEN用于治疗和预防前列腺癌的用途

    公开(公告)号：EP1646385A2

    公开(公告)日：2006-04-19

    申请号：EP04816781.1

    申请日：2004-07-21

    申请人： Cedars-Sinai Medical Center

    发明人： AGUS, David, B.

    IPC分类号： A61K31/445

    CPC分类号： A61K31/445 ,  A61K31/4535

    摘要： Disclosed herein is a method for treating and preventing prostate cancer, and particularly androgen-independent prostate cancer, the method including administering to a mammal a benzothiopene having Formula (I) or pharmaceutically acceptable salts or prodrugs thereof, wherein R and R1, are each independently selected from the group consisting of hydrogen, -COR2, -COR3, and R4; R2 is selected from the group consisting of hydrogen, C1-C14 alkyl, C1-C3 chloroalkyl, C1-C3 fluoroalkyl, C5-C7 cycloalkyl, C1-C4 alkoxy, and phenyl; R3 is phenyl with at least one substitution selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, hydroxy, nitro, chloro, fluoro, trichloromethyl, and trifluoromethyl; R4 is selected from the group consisting of C1-C4 alkyl, C5-C7 cycloalkyl, and benzyl; and R5 is selected from the group consisting of oxygen and -C=O. The method may further include the administration of an estrogen lowering drug to enhance efficacy of the compound of the present invention.

    BI-DIRECTIONAL SYSTEM FOR MASS SPECTROMETRY
    3.
    发明公开
    BI-DIRECTIONAL SYSTEM FOR MASS SPECTROMETRY 审中-公开
    用于质谱分析的双向系统

    公开(公告)号：EP1854124A2

    公开(公告)日：2007-11-14

    申请号：EP06736280.6

    申请日：2006-02-28

    申请人： Cedars-Sinai Medical Center

    发明人： AGUS, David, B.

    IPC分类号： H01J49/00

    CPC分类号： H01J49/38

    摘要： The present invention relates to a system and method for mass spectrometry (100) that allows for bi-directional introduction of collections of charged particles into the magnetic field of a mass spectrometer. More particularly, the present invention includes a system for mass spectrometry (100)(e.g., an FTMS mass spectrometer) with a cylindrical magnet (101) configured to receive and measure the cyclotron frequencies (104) of charged particles that are introduced (102, 103) into the cylindrical magnet (101) from eith of the two axial ends thereof. Methods of the invention relate to performing mass spectrometry analysis on collections of charged particles that are introduced (102, 103), serially, simultaneously or both, into a cylindrical magnet (101) from opposing axial ends thereof. The present invention exhibits significantly increased magnet throughput relative to currently available devices, by allowing flow in the opposite direction to a second detector, e.g., during ion processing time of a first detector.

    摘要翻译： 本发明涉及用于质谱（100）的系统和方法，其允许将带电粒子的集合双向引入质谱仪的磁场中。 更具体地说，本发明包括具有圆柱形磁体（101）的质谱系统（100）（例如FTMS质谱仪），其被配置为接收和测量引入的带电粒子的回旋频率（104） 103）从其两个轴向端的第一端插入到圆柱形磁体（101）中。 本发明的方法涉及对从其相反轴向端部串行，同时或两者引入（102,103）到圆柱形磁体（101）中的带电粒子集合进行质谱分析。 通过允许例如在第一检测器的离子处理时间期间沿与第二检测器相反的方向流动，相对于当前可用的装置，本发明表现出显着增加的磁体通过量。

    GEFITINIB (IRESSA) FOR THE TREATMENT OF CANCER
    4.
    发明授权
    GEFITINIB (IRESSA) FOR THE TREATMENT OF CANCER 有权
    吉非替尼（IRESSA）一种癌的治疗

    公开(公告)号：EP1509230B1

    公开(公告)日：2007-01-03

    申请号：EP03734386.0

    申请日：2003-06-04

    申请人： Cedars-Sinai Medical Center

    发明人： AGUS, David, B.

    IPC分类号： A61K31/5377 ,  A61P35/00

    CPC分类号： C12Q1/485 ,  A61K31/00 ,  A61K31/5377 ,  G01N33/574 ,  G01N33/57423 ,  G01N33/57434 ,  G01N2800/52

    摘要： Described herein are methods for treating cancer and other disease conditions in individuals who have either developed a resistance to conventional tyrosine kinase inhibitor (TKI) therapy or who are non-responsive ab initio to conventional TKI therapy. In various embodiments, the methods include administering to a patient a resistance-surmounting quantity of a TKI on a weekly or semi-weekly basis. Alternate embodiments of the present invention include a diagnostic method for assessing an individual's probability of being resistant to TKI therapy, based upon an expression level of epithelial membrane protein-1 (EMP-1); one of the genes believed to be responsible for TKI resistance. The methods of the present invention may be particularly useful in the treatment of lung, breast, prostate, ovarian, brain and colon cancers. The methods of the present invention may be effective in blocking the HER-2 kinase domain either in addition to or in lieu of blocking the EGFR kinase domain.

    METHOD OF TREATING CANCER USING KINASE INHIBITORS
    5.
    发明公开
    METHOD OF TREATING CANCER USING KINASE INHIBITORS 有权
    吉非替尼（IRESSA）一种癌的治疗

    公开(公告)号：EP1509230A2

    公开(公告)日：2005-03-02

    申请号：EP03734386.0

    申请日：2003-06-04

    申请人： CEDARS-SINAI MEDICAL CENTER

    发明人： AGUS, David, B.

    IPC分类号： A61K31/5377 ,  A61P35/00

    CPC分类号： C12Q1/485 ,  A61K31/00 ,  A61K31/5377 ,  G01N33/574 ,  G01N33/57423 ,  G01N33/57434 ,  G01N2800/52

    摘要： Described herein are methods for treating cancer and other disease conditions in individuals who have either developed a resistance to conventional tyrosine kinase inhibitor (TKI) therapy or who are non-responsive ab initio to conventional TKI therapy. In various embodiments, the methods include administering to a patient a resistance-surmounting quantity of a TKI on a weekly or semi-weekly basis. Alternate embodiments of the present invention include a diagnostic method for assessing an individual's probability of being resistant to TKI therapy, based upon an expression level of epithelial membrane protein-1 (EMP-1); one of the genes believed to be responsible for TKI resistance. The methods of the present invention may be particularly useful in the treatment of lung, breast, prostate, ovarian, brain and colon cancers. The methods of the present invention may be effective in blocking the HER-2 kinase domain either in addition to or in lieu of blocking the EGFR kinase domain.